T Rowe Price Group Inc vs GeneDx Holdings Corp — how do they compare? T Rowe Price Group Inc trades at $115.59 (market cap $25.14B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: T Rowe Price Group Inc is far larger — about 14× GeneDx Holdings Corp's market cap, and T Rowe Price Group Inc pays a 4.43% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TROW | WGS | |
|---|---|---|
Market Cap | $25.14B | $1.80B |
Sector | Financials | Technology |
52-Week High | $120.16 | $167.51 |
52-Week Low | $86.19 | $34.51 |
Enterprise Value | $21.85B | $1.80B |
Dividend Yield | 4.43% | — |
Trailing returns across standard periods
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →